Chemo plus new vaccines versus chemo alone after pancreatic surgery
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether adding two study medicines (an immune-based vaccine treatment plus atezolizumab) to standard chemo helps prevent pancreatic cancer from coming back after surgery. It compares the combination against standard chemo alone, looking at safety and how well it prevents relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma (PDAC) confirmed by biopsy/pathology.
- Your surgery removed the tumor completely (R0 or R1) and a doctor confirms no visible disease within 28 days before starting.
- Your surgery was 6 to 12 weeks before starting the trial, and you have recovered enough to receive all study medicines.
- You can’t have had any prior chemo, radiation, or other anti-cancer treatment for pancreatic cancer before this trial.
- Blood tests and organ function (like blood counts and liver/kidney measures) must meet study safety limits; you also must not have significant nerve pain (neuropathy) before starting.
- You must not be pregnant or breastfeeding, and you must follow strict birth-control rules during treatment and for months after the last doses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
Hear when a new Adenocarcinoma, Pancreatic Ductal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.